Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Wilate

Phase 3Biologic

Wilate is one of 64 biologic programs targeting Von Willebrand disease. It is currently in Phase 3.

3

Indications

7

Total Trials

2

Active Trials

63

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Hemophilia aActive, not recruiting

Severe Hemophilia aActive, not recruiting

Von Willebrand DiseasePhase 3

Active, not recruiting

Hemophilia aPreclinical

Active, not recruiting

Severe Hemophilia aPhase 3

Active, not recruiting

Competition

Competitive Landscape

93 competitors in Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Rituxan

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Eptacog Alfa

Qfitlia

GGenzyme, a Sanofi Company

Valoctocogene Roxaparvovec

BioMarin Pharmaceutical

Recombinant Factor VIII

Rfviia

Marstacimab

PF-06741086

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Post-ApprovalRecruiting

Concentration

NCT04555785

Q2 2029

Hemophilia a

NCT04023019

Clinical

Trials by Indication[1]

Hemophilia A1 trial

Treatment of Hemophilia A Patients With FVIII Inhibitors

Recruiting·EEmory University··NCT04023019·120 enrolled

Concentration1 trial

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT04555785·120 enrolled

Severe Hemophilia a1 trial

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Completed· Octapharma logo

Octapharma·Phase 3·NCT02954575·57 enrolled

Efficacy and Safety1 trial

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Completed· Octapharma logo

Octapharma·Phase 3·NCT04052698·43 enrolled

Immunogenicity1 trial

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Completed· Octapharma logo

Octapharma·Phase 3·NCT03376516·11 enrolled

2 more indications

Von Willebrand disease1 trial

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Completed· Octapharma logo

Octapharma·Phase 3·NCT04953884·12 enrolled

Unspecified1 trial

INdividualized ITI Based on Fviii(ATE) Protection by VWF

Terminated·UUniversity of California, Davis·Phase 4·NCT03204539·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Wilate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Wilate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Wilate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Related News